Discussion about several potential drawbacks of PEGylated therapeutic proteins

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 3, 2014, Pages 335-339

  Zhang, Fan ^a   Liu, Mu Rong ^b   Wan, Hai Tong ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b BIODOOR Biotechnology Co Ltd of Hangzhou City in Zhejiang Province   (China)

Author keywords

PEGylation; Potential risk; Therapeutic protein

Indexed keywords

ANTIBODY; ASPARAGINASE MACROGOL; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; IMMUNOGLOBULIN M ANTIBODY; LIPOSOME; MACROGOL; PEGADEMASE; PEGAPTANIB; PEGINESATIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGLOTICASE; PEGVISOMANT; POLYETHYLENE GLYCOL ANTIBODY; PROTEIN DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; BIOMEDICINE; BIOTECHNOLOGY; CELL VACUOLE; CHEMICAL MODIFICATION; CYTOPLASM; DRUG ANTIGENICITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MIXTURE; HUMAN; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PLASMA CLEARANCE; REVIEW; STATIC ELECTRICITY;

ANTIBODY FORMATION; HUMANS; POLYETHYLENE GLYCOLS; PROTEINS; VACUOLES;

EID: 84896919120     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00661     Document Type: Review

References (72)

1. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials, 22, 405-417 (2001).
2. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem., 252, 3582-3586 (1977).
3. Levy Y, Hershfield MS, Fernandez-Mejia C, Polmar SH, Scudiery D, Berger M, Sorensen RU. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J. Pediatr., 113, 312-317 (1988).
4. Graham ML. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev., 55, 1293-1302 (2003).
5. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev., 54, 547-570 (2002).
6. Monkarsh SP, Ma Y, Aglione A, Bailon P, Ciolek D, Debarbieri B, Graves MC, Hollfelder K, Michel H, Palleroni A, Porter JE, Russoman E, Roy S, Pan Y-CE. Positional isomers of monopegylated interferon α-2a: Isolation, characterization, and biological activity. Anal. Biochem., 247, 434-440 (1997).
7. Hak LJ, Relling MV, Cheng C, Pei D, Wang B, Sandlund JT, Rubnitz J, Pui CH. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia, 18, 1072-1077 (2004).
8. Roelfsema F, Biermasz NR, Pereira AM, Romijn JM. Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int. J. Nanomedicine, 1, 385-398 (2006).
9. Pasut G, Veronese FM. Polymer-drug conjugation recent achievements and general strategies. Prog. Polym. Sci., 32, 933-961 (2007).
10. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr. Hematol. Rep., 4, 436-440 (2005).
11. Blick SKA, Curran MP. Certolizumab pegol. BioDrugs, 21, 195-201, discussion, 202-203 (2007).
12. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv. Drug Deliv. Rev., 60, 59-68 (2008).
13. Fishbane S, Roger SD, Martin E, Runyan G, O'Neil J, Qiu P, Locatelli F. Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. Clin. J. Am. Soc. Nephrol., 8, 538-545 (2013).
14. Morar AS, Schrimsher JL, Chavez MD. PEGylation of proteins: A structural approach. Biopharm. Int., 19, 34-48 (2006).
15. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev., 54, 459-476 (2002).
16. Zalipsky S, Harris JM. Introduction to chemistry and biological applications of poly(ethylene glycol). ACS Symp. Ser., 680, 1-13 (1997).
17. Zalipsky S. Functionalized poly(ethylene glycol)s for preparation of biologically relevant conjugates. Bioconjug. Chem., 6, 150-165 (1995).
18. Dreborg S, Akerblom E. Immunotherapy with monomethoxy-polyethylene glycol modified allergens. Crit. Rev. Ther. Drug, 6, 315-365 (1990).
19. Richter AW, Åkerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Appl. Immunol., 70, 124-131 (1983).
20. Sroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell. Mol. Biol. Lett., 10, 37-47 (2005).
21. Armstrong JK, Wenby RB, Meiselman HJ, Fisher TC. In vivo survival of poly(ethylene glycol)-coated red blood cells in the rabbit. Blood, 102, 94A (2003).
22. Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug. Chem., 11, 258-266 (2000).
23. Cheng TL, Cheng CM, Chen BM, Tsao DA, Chuang KH, Hsiao SW, Lin YH, Roffler SR. Monoclonal anti-body-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. Bioconjug. Chem., 16, 1225-1231 (2005).
24. Shimizu T, Ichihara M, Yoshioka Y, Ishida T, Nakagawa S, Kiwada H. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol. Pharm. Bull., 35, 1336-1342 (2012).
25. Leger RM, Arndt P, Garratty G, Armstrong JK, Meiselman HJ, Fisher TC. Normal donor sera can contain antibodies to polyethylene glycol (PEG). Transfusion, 41, 29S (2001).
26. Armstrong JK, Leger R, Wenby RB, Meiselman HJ, Garratty G, Fisher TC. Occurrence of an antibody to poly(ethylene glycol) in normal donors. Blood, 102, 556A (2003).
27. Garratty G. Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs. Transfus. Med. Rev., 18, 245-256 (2004).
28. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: Facts and fiction. Pharm. Res., 30, 1729-1734 (2013).
29. Garay RP, Labaune JP. Immunogenicity of polyethylene glycol. Open Conf. Proc. J., 2, 104-107 (2011).
30. Armstrong JK. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). Pegylated protein drugs: Basic science and clinical applications. (Veronese FM ed.) Birkhäuser, Basel, pp. 147-168 (2009).
31. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev., 55, 1261-1277 (2003).
32. de Groot MC, van Zwieten-Boot BJ, Van Grootheest AC. Severe adverse reactions after the use of sulphur hexafluoride (SonoVue) as an ultrasonographic contrast agent. Ned. Tijdschr. Geneeskd., 148, 1887-1888 (2004).
33. Geleijnse ML, Nemes A, Vletter WB, Michels M, Soliman OI, Caliskan K, Galema TW, ten Cate FJ. Adverse reactions after the use of sulphur hexafluoride (SonoVue) echo contrast agent. J. Cardiovasc. Med., 10, 75-77 (2009).
34. Pérez-Pérez L, García-Gavín J, Piñeiro B, Zulaica A. Biologic-induced urticaria due to polysorbate 80: usefulness of prick test. Br. J. Dermatol., 164, 1119-1120 (2011).
35. Dams ETM, Laverman P, Oyen WJG, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC. van der Meer, Boerman OC. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther., 292, 1071-1079 (2000).
36. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther., 298, 607-612 (2001).
37. Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release, 88, 35-42 (2003).
38. Ishida T, Ichihara M, Wang X, Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release, 115, 243-250 (2006).
39. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm., 354, 56-62 (2008).
40. Ishida T, Kashima S, Kiwada H. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J. Control. Release, 126, 162-165 (2008).
41. Lu W, Wan J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J. Control. Release, 118, 38-53 (2007).
42. Laboureur P, Langlois C. Urate oxidase of Aspergillus flavus. I. isolation, purification, properties. Bull. Soc. Chim. Biol. (Paris), 50, 811-825 (1968).
43. Legoux R, Delpech B, Dumont X, Guillemot JC, Ramond P, Shire D, Caput D, Ferrara P, Loison G. Cloning and expression in Escherichia coli of gene encoding Aspergillus flavus urate oxidase. J. Biol. Chem., 267, 8565-8570 (1992).
44. Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine, 78, 35-40 (2011).
45. Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol. Biol. Evol., 19, 640-653 (2002).
46. Colonna C, Conti B, Perugini P, Pavanetto F, Modena T, Dorati R, Iadarola P, Genta I. Site-directed PEGylation as successful approach to improve the enzyme replacement in the case of prolidase. Int. J. Pharm., 358, 230-237 (2008).
47. Song S, Liu D, Peng J, Sun Y, Li Z, Gu JR, Xu Y. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm., 363, 155-161 (2008).
48. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs, 22, 315-329 (2008).
49. Morille M, Passirani C, Letrou-Bonneval E, Benoit JP, Pitard B. Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting. Int. J. Pharm., 379, 293-300 (2009).
50. Zhou J, Cai ZH, Li L, Kou C, Gao YF. Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris. Eur. J. Pharm. Biopharm., 72, 412-417 (2009).
51. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther., 8, R12 (2006).
52. Tsuji J, Hirose K, Kasahara E, Naitoh M, Yamamoto I. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. Int. J. Immunopharmacol., 7, 725-730 (1985).
53. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. JAMA, 306, 711-720 (2011).
54. Hempel G, Lanvers-Kaminsky C, Muller HJ, Wurtwein G, Boos J. A population pharmacokinetic model describing the activity-time-course of PEG-asparaginase in children. Blood, 11, 751A (2004).
55. Müller HJ, Löning L, Horn A, Schwabe D, Gunkel M, Schrappe M, von Schütz V, Henze G, Casimiro da Palma J, Ritter J, Pinheiro JP, Winkelhorst M, Boos J. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br. J. Haematol., 110, 379-384 (2000).
56. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer, 110, 103-111 (2007).
57. Caliceti P, Schiavon O, Veronese FM. Immunological properties of uricase conjugated to neutral soluble polymers. Bioconjug. Chem., 12, 515-522 (2001).
58. Sherman MR, Williams LD, Sobczyk MA, Michaels SJ, Saifer MG. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug. Chem., 23, 485-499 (2012).
59. Judge A, McClintock K, Phelps JR, MacLachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther., 13, 328-337 (2006).
60. Bendele A, Seely J, Richey C, Sennello G, Shopp G. Short communication: renal tubular vacuolation in animals treated with polyethyleneglycol-conjugated proteins. Toxicol. Sci., 42, 152-157 (1998).
61. Rudmann DG, Alston JT, Hanson JC, Heidel S. High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol. Pathol., 41, 970-983 (2013).
62. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci., 83, 601-606 (1994).
63. EPAR. "Cimzia : EPAR-Public assessment report.": 〈http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public- assessment-report/human/001037/WC500069735.pdf〉, cited 20 October, 2013.
64. FDA. "Center for drug evaluation and research.": 〈http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/ 125293Orig1s000PharmR.pdf〉, cited October 17, 2013.
65. FDA. "Center for drug evaluation and research.": 〈http://www.accessdata.fda.gov/drugsatfda-docs/nda/2003/ 21-106-Somavert-Pharmr-P1.pdf〉, cited 19 October, 2013.
66. Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tendler CL. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J. Clin. Oncol., 20, 3841-3849 (2002).
67. Gregoriadis G, Jain S, Papaioannou I, Laing P. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. International journal of pharmaceutic. Int. J. Pharm., 300, 125-130 (2005).
68. On drug delivery. "Novel polymers for enhancing therapeutic half-life and drug targeting.": 〈http://www.ondrugdelivery.com/ publications/Injectable%20Formulations%202011/WEP.pdf〉, cited 18 August, 2013.
69. Pasut G, Veronese FM. State of the art in PEGylation: The great versatility achieved after forty years of research. J. Control. Release, 161, 461-472 (2012).
70. Kerwin BA, Chang BS, Gegg CV, Gonnelli M, Li T, Strambini GB. Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus. Protein Sci., 11, 1825-1833 (2002).
71. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol., 22, 868-876 (2011).
72. Geething NC, To W, Spink BJ, Scholle MD, Wang CW, Yin Y, Yao Y, Schellenberger V, Cleland JL, Stemmer WP, Silverman J. Gcg- XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS ONE, 5, e10175 (2010).